Centessa Pharmaceuticals plc
CNTA
$39.76
$0.060.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 61.20% | 2.11% | -2.20% | 6.69% | -8.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 74.26% | -8.19% | 15.91% | 24.27% | 26.84% |
| Operating Income | -159.20% | 8.19% | -15.91% | -24.27% | 14.72% |
| Income Before Tax | -216.88% | 39.53% | -30.43% | -14.97% | 34.15% |
| Income Tax Expenses | -39.16% | -149.71% | -72.70% | 10.35% | 190.44% |
| Earnings from Continuing Operations | -203.20% | 40.57% | -28.96% | -14.90% | 31.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -203.20% | 40.57% | -28.96% | -14.90% | 31.31% |
| EBIT | -159.20% | 8.19% | -15.91% | -24.27% | 14.72% |
| EBITDA | -160.26% | 8.19% | -15.99% | -24.42% | 14.76% |
| EPS Basic | -162.65% | 44.73% | -11.75% | 5.90% | 48.41% |
| Normalized Basic EPS | -174.61% | 18.61% | -10.87% | 5.85% | 49.08% |
| EPS Diluted | -162.65% | 44.73% | -11.75% | 5.90% | 48.41% |
| Normalized Diluted EPS | -174.61% | 18.61% | -10.87% | 5.85% | 49.08% |
| Average Basic Shares Outstanding | 15.42% | 7.52% | 15.41% | 22.09% | 33.18% |
| Average Diluted Shares Outstanding | 15.42% | 7.52% | 15.41% | 22.09% | 33.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |